The present invention provides 5-membered heterocycle compounds represented by the following general formula (I):
The present compounds have a superior acid secretion inhibitory effect, and shows an antiulcer activity and the like.
The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I)
wherein R
1
is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R
2
is an optionally substituted C
6-14
aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, R
3
and R
4
are each a hydrogen atom, or one of R
3
and R
4
is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R
5
is an alkyl group or a salt thereof.
The present invention aims to provide an iminopyridine derivative compound having an α
1D
adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like.
The present invention provides a compound represented by the formula
wherein each symbol is as defined in the specification, or a salt thereof.
The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (VIII), which includes reducing compound (III) and hydrolyzing the reduced product to give compound (IV), subjecting compound (IV) to a sulfonylation reaction to give compound (VI), and subjecting compound (VI) to an amination reaction.
The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity, which is represented by the formula (I)
wherein R
1
is an optionally substituted cyclic group, R
2
is a substituent, R
3
is an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a halogen atom, a cyano group or a nitro group, R
4
and R
5
are each a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a halogen atom, a cyano group or a nitro group, R
6
and R
6′
are each a hydrogen atom or an alkyl group, and n is an integer of 0-3, or a salt thereof.